Close Menu

NEW YORK – Ortho Clinical Diagnostics today announced it has received CE marking for an enhanced version of its Vitros NT-proBNP II assay to diagnose heart failure and enable risk stratification of heart failure and acute coronary syndrome.

Clinicians can also use the assay to assess heart failure severity and the increased risk of cardiovascular events and mortality in patients who have stable coronary artery disease, Raritan, New Jersey-based Ortho said.

N-terminal pro brain natriuretic peptide (NT-proBNP) is used in diagnostic tests to diagnose heart failure.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.